| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/18/2004 | CA2159485C Anti-oxydant alkylaryl polyether alcohol polymers |
| 05/18/2004 | CA2090911C Aqueous pharmaceutical formulations of sodium cromoglycate |
| 05/18/2004 | CA2076010C Microspheres, preparation process and use thereof |
| 05/13/2004 | WO2004039994A1 Sodium chondroitin sulfate, chondroitin sulfate-containing material and processes for producing the same |
| 05/13/2004 | WO2004039944A2 Tri-block polymers for nanosphere-based drug or gene delivery |
| 05/13/2004 | WO2004039869A1 High-molecular weight derivatives of camptothecins |
| 05/13/2004 | WO2004039830A2 Bioactivation of particles |
| 05/13/2004 | WO2004039817A1 Cardiolipin molecules and method of synthesis |
| 05/13/2004 | WO2004039454A1 Formulations containing melatonin, ginkgo biloba, and biotin |
| 05/13/2004 | WO2004039411A2 Solid and semi-solid polymeric ionic conjugates |
| 05/13/2004 | WO2004039410A2 Liquid conjugates of solid pharmaceuticals |
| 05/13/2004 | WO2004039390A1 Ointment composition for treating decubitus ulcers and methods for its making and its use |
| 05/13/2004 | WO2004039382A1 Enhanced production of clotting factors by cryoprecipitation |
| 05/13/2004 | WO2004039369A1 Daily melatonin dosing units |
| 05/13/2004 | WO2004039360A1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 05/13/2004 | WO2004039348A1 Formulations for topical delivery of bioactive substances and methods for their use |
| 05/13/2004 | WO2004039335A2 Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
| 05/13/2004 | WO2004039326A2 Propofol with cysteine |
| 05/13/2004 | WO2004032898A3 Controlled release system containing sucrose acetate isobutyrate |
| 05/13/2004 | WO2004030623A3 Nitroxide radioprotector formulations and methods of use |
| 05/13/2004 | WO2004022102A3 Pharmaceutical formulation with non-steroidal antiphlogistic agents and nucleic acids for the internalization of nucleic acids into eucaryotic cells |
| 05/13/2004 | WO2004019990A9 Therapeutic system targeting pathogen proteases and uses thereof |
| 05/13/2004 | WO2004017943A3 Non-vesicular cationic lipid formulations |
| 05/13/2004 | WO2004014335A3 Dual-spike release formulation for oral drug delivery |
| 05/13/2004 | WO2003094888A9 Processes for forming a drug delivery device |
| 05/13/2004 | WO2003090684B1 Polymer compositions containing a macrocyclic triene compound |
| 05/13/2004 | WO2003082207A3 Volume efficient controlled release dosage form |
| 05/13/2004 | WO2003080022A3 Analgesics for nasal administration |
| 05/13/2004 | WO2003070280A3 Absorption enhancing agent |
| 05/13/2004 | WO2003066859A3 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 05/13/2004 | WO2003059194A3 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 05/13/2004 | WO2003051454A3 Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| 05/13/2004 | WO2003045420A3 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization |
| 05/13/2004 | WO2003037337A8 Depot formulations of iloperidone and a star polymer |
| 05/13/2004 | WO2003037291A8 Cream for treatment of skin injured by the sun |
| 05/13/2004 | WO2003034903B1 Psma antibodies and protein multimers |
| 05/13/2004 | WO2003005636A8 Secure header information for multi-content e-mail |
| 05/13/2004 | WO2002085447A8 Microprojection array having a beneficial agent containing coating |
| 05/13/2004 | WO2002072073A3 Pharmaceutical formulation comprising atorvastatin calcium |
| 05/13/2004 | WO2002051387A8 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 05/13/2004 | WO2002048377A8 Polynucleotide encoding chimeric protein and related vectors, cells, and methods of expression thereof |
| 05/13/2004 | WO2002038171A9 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/13/2004 | WO2002030397A9 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors |
| 05/13/2004 | US20040092911 Ophthalmic drug delivery device |
| 05/13/2004 | US20040092820 Device and process for quantifying bodies by means of ultrasound |
| 05/13/2004 | US20040092723 Immunoglobulin fusion for diagnosis and treatment of cancer and viral diseases |
| 05/13/2004 | US20040092721 Ligand comprising monoclonal antibody for treatment of tumors and prevention of tumor metastasis; antitumor agents |
| 05/13/2004 | US20040092597 Fenofibrate compositions having high bioavailability |
| 05/13/2004 | US20040092577 In situ insertion of paclitaxel; powder regenerated as injection |
| 05/13/2004 | US20040092544 Synergistic mixture containing dopamine agent; muscular disorders; analgesics |
| 05/13/2004 | US20040092542 Tamper-resistant oral opioid agonist formulations |
| 05/13/2004 | US20040092531 Active substance combination containing an opioid having a fentanyl-type structure and ketamine |
| 05/13/2004 | US20040092527 Itraconazole bioavailability |
| 05/13/2004 | US20040092494 Method of increasing testosterone and related steroid concentrations in women |
| 05/13/2004 | US20040092473 Method for nucleic acid transfection of cells |
| 05/13/2004 | US20040092468 Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| 05/13/2004 | US20040092467 Biological carriers for the delivery of proteins or peptides |
| 05/13/2004 | US20040092455 Carbohydrates conjugated to optionally protected 4-hydroxybutyric acid; enhance the uptake of the drug and allows effective drug delivery to treat GHB-treatable disorders such as sleep disorders or drug withdrawal |
| 05/13/2004 | US20040092452 Adding formulation to dissolution medium having osmolarity of 100-550 mOsmol/L and ph of 7-12, maintaining at 0-50 degrees above glass transition temperature of polylactide and determining amount of peptide in the sample |
| 05/13/2004 | US20040092449 Administering a luminal cholecystokinin releasing factor polypeptide; treating obesity |
| 05/13/2004 | US20040092437 Using genetically engineered mammalian plasma protein to prevent and treat transplant rejection, graft-versus-host and autoimmune diseases; side effect reduction and tumor therapy |
| 05/13/2004 | US20040092434 Oligopeptides; antitumor agents, antiinflammatory agents, antiischemic agents, vision defects |
| 05/13/2004 | US20040092428 Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| 05/13/2004 | US20040092017 Binary viral expression system in plants |
| 05/13/2004 | US20040092015 Coupling; binding aldehyde compound forming hydrazone compound; lipophilic vector |
| 05/13/2004 | US20040091553 Composition and method for mammary disinfection during winter conditions |
| 05/13/2004 | US20040091546 Made of amphiphilic copolymers at a predictable/controlled size and yield; mixing a solution of an amphiphilic copolymer in a process solvent with a non-process solvent; flash precipitation in a product solvent; solubility; stability |
| 05/13/2004 | US20040091545 Entrapping the acid in a methacrylic acid copolymer by acidifying a basic solution or dispersion to cause formation of a precipitate which is then collected and dried; odorless dietary supplement for cardio-vascular systems |
| 05/13/2004 | US20040091541 Solid matrix therapeutic compositions |
| 05/13/2004 | US20040091539 A topical composition in the form of a solid stick comprising a corticosteroid, petrolatum, a wax, propylene glycol, and an emulsifier; an outer protective covering being constructed to prevent hand contact; anhydrous; skin disorders |
| 05/13/2004 | US20040091536 Stability of masking of the taste when the reconstitutable, dry suspension contains granules having a core of drug and excipients (thickener, preservative and buffer) and at least three successive layers of coating; organoleptic |
| 05/13/2004 | US20040091530 Dosage forms for oral admistration resulting in a maximum secretagogue plasma concentration, Cmax, less than 80% Cmax of that when an equal dose is administered in an immediate release form; osmotic tablet of a asymetric membrane; 6 hours |
| 05/13/2004 | US20040091529 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| 05/13/2004 | US20040091527 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 05/13/2004 | US20040091523 Pharmaceutical composition and the process for its preparation |
| 05/13/2004 | US20040091522 Lipid microparticles by cryogenic micronization |
| 05/13/2004 | US20040091517 Use of polyphospate as a tooth erosion inhibitors in acidic compositions |
| 05/13/2004 | US20040091516 Printing or dispensing a suspension such as three-dimensional printing of dosage forms |
| 05/13/2004 | US20040091510 Methods of dispersing at least one coloring agent using at least one heteropolymer |
| 05/13/2004 | US20040091506 Topical antifungal treatment |
| 05/13/2004 | US20040091495 Protein |
| 05/13/2004 | US20040091491 An immune response modifier portion such as a Toll-like receptor or an imidazoquinoline compound paired with an antigenic portion; use of toll-like receptor improves immune response over conventional immune response modifiers |
| 05/13/2004 | US20040091489 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
| 05/13/2004 | US20040091488 Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof |
| 05/13/2004 | US20040091484 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/13/2004 | US20040091482 Humanized collagen antibodies and related methods |
| 05/13/2004 | US20040091452 Calcitonin drug-oligomer conjugates, and uses thereof |
| 05/13/2004 | US20040091443 Conditioning polymer encapsulated in lipid vesicle |
| 05/13/2004 | US20040091425 Polyvinyl alcohol microspheres, and methods for making and therapeutic uses of the same |
| 05/13/2004 | US20040091421 The invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable |
| 05/13/2004 | US20040089753 Wet milling process |
| 05/13/2004 | DE10251256A1 Transdermales Wirkstoffabgabesystem für Oxybutynin Transdermal drug delivery system for oxybutynin |
| 05/13/2004 | DE10250646A1 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents |
| 05/13/2004 | DE10249890A1 Gallensäurekonjugate und damit gebildete Partikel Gallensäurekonjugate and thus formed particles |
| 05/13/2004 | DE10249552A1 Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel Water-soluble iron-carbohydrate complexes, their preparation and pharmaceutical compositions containing them |
| 05/13/2004 | CA2543370A1 Formulations for topical delivery of bioactive substances and methods for their use |
| 05/13/2004 | CA2504361A1 Formulations containing melatonin, ginkgo biloba, and biotin |
| 05/13/2004 | CA2504345A1 Liquid conjugates of solid pharmaceuticals |
| 05/13/2004 | CA2504341A1 Melatonin daily dosing units |
| 05/13/2004 | CA2503956A1 Propofol with cysteine |